Zurück

Wählen Sie Ihre Region

Corporate

Europa:

Flagge Albanien Albanien Flagge Bosnien-Herzegowina Bosnien-Herzegowina Flagge Bulgarien Bulgarien Flagge Kroatien Kroatien Flagge Zypern Zypern Flagge Montenegro Montenegro Flagge Tschechien Tschechien Flagge Dänemark Dänemark Flagge Estland Estland Flagge Spanien Spanien Flagge Kosovo Kosovo Flagge Litauen Litauen Flagge Lettland Lettland Flagge Luxemburg Luxemburg Flagge Mazedonien Mazedonien Flagge Deutschland Deutschland Flagge Polen Polen Flagge Portugal Portugal Flagge Rumänien Rumänien Flagge Serbien Serbien Flagge Slowakei Slowakei Flagge Slowenien Slowenien Flagge Schweiz Schweiz Flagge Schweden Schweden Flagge Türkei Türkei Flagge Ungarn Ungarn Flagge Großbritannien Großbritannien Flagge Italien Italien

Asien:

Flagge UAE UAE Flagge Hong Kong Hong Kong Flagge Kuwait Kuwait Flagge Libanon Libanon

Afrika:

Flagge Südafrika Südafrika

Vereinbaren Sie ein Beratungsgespräch über Stammzellen

Mehr erfahren

Kontaktieren Sie uns noch heute!

Möchten Sie mehr über unsere Dienstleistungen erfahren? Füllen Sie das untenstehende Formular aus, und wir werden uns so schnell wie möglich mit Ihnen in Verbindung setzen, um Ihnen alle notwendigen Informationen zu geben und Ihre Fragen zu beantworten.

    Wir möchten Sie darauf hinweisen, dass die im Formular angegebenen personenbezogenen Daten von FamiCord Suisse mit Sitz in der Schweiz (BusinessPark Zug Sumpfstrasse 26, 6302 Zug) zur telefonischen Kontaktaufnahme im Zusammenhang mit der Erteilung von Serviceinformationen verarbeitet werden.

    Obraz

    Unsere
    Transplantationen

    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:

    Obraz
    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:
    Nr. Quelle Quellentyp Diagnose Medizinbereich Anwendungsjahr Therapie Land Alter des Empfängers
    1801 Apheresis Allogeneic plasma cell leukemia Hematology 2024 Standard Therapy USA 59
    1802 Apheresis Allogeneic Fibrolamellar Carcinoma Hematology 2024 Standard Therapy Czechia 41
    1803 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 59
    1804 Apheresis Allogeneic post-ET Myelofibrose Hematology 2024 Standard Therapy Austria 61
    1805 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 55
    1806 Apheresis Allogeneic Myeloma Multiplex Hematology 2024 Standard Therapy Poland 67
    1807 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Spain 45
    1808 Apheresis Allogeneic Myelofibrose Hematology 2024 Standard Therapy Spain 69
    1809 Apheresis Allogeneic Myelofibrose Hematology 2024 Standard Therapy Poland 60
    1810 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy USA 53
    1811 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy France 35
    1812 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 69
    1813 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Norway 18
    1814 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Germany 51
    1815 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 62
    1816 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Hungary 56
    1817 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy USA 19
    1818 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Spain 67
    1819 Apheresis Allogeneic Hemophagocytic Lymphohistiocytosis Hematology 2024 Standard Therapy United Kingdom 48
    1820 Apheresis Allogeneic Non-Hodgkin's lymphoma Hematology 2024 Standard Therapy NETHERLANDS 61
    1821 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 29
    1822 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 62
    1823 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Israel 63
    1824 Apheresis Allogeneic ETP-Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 35
    1825 Apheresis Allogeneic Hodgkin lymphoma Hematology 2024 Standard Therapy Poland 4
    1826 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 23
    1827 Apheresis Allogeneic Fanconi Anemia Hematology 2024 Standard Therapy USA 27
    1828 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 69
    1829 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 44
    1830 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 49
    1831 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 20
    1832 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy France 50
    1833 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 74
    1834 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Austria 49
    1835 Apheresis Allogeneic Post-PV Myelofibrose Hematology 2024 Standard Therapy Germany 59
    1836 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 66
    1837 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 58
    1838 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 55
    1839 Apheresis Allogeneic Myelofibrosis Hematology 2024 Standard Therapy France 70
    1840 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy France 54
    1841 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 68
    1842 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 41
    1843 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy USA 31
    1844 Apheresis Allogeneic Other leukemia Hematology 2024 Standard Therapy Italy 31
    1845 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Sweden 42
    1846 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 43
    1847 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 52
    1848 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 64
    1849 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 60
    1850 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 70
    1851 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
    1852 Apheresis Allogeneic Primary myelofibrosis Hematology 2024 Standard Therapy Germany 55
    1853 Apheresis Autologous Amyloid Light-Chain Amyloidosis Hematology 2024 Standard Therapy Germany 55
    1854 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 61
    1855 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
    1856 Apheresis Autologous Epstein–Barr Virus Positive Diffuse Large B-Cell Lymphoma Hematology 2024 Standard Therapy Germany 63
    1857 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 69
    1858 Apheresis Autologous Angioimmunoblastic T-cell lymphoma Hematology 2024 Standard Therapy Germany 58
    1859 Apheresis Allogeneic Acute lymphoblastic leukemia Hematology 2024 Standard Therapy Germany 19
    1860 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 66
    1861 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 61
    1862 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Canada 16
    1863 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 61
    1864 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 75
    1865 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2024 Standard Therapy USA 62
    1866 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2024 Standard Therapy France 66
    1867 Apheresis Allogeneic B-Cell Lymphoma Hematology 2024 Standard Therapy Canada 70
    1868 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 60
    1869 Apheresis Allogeneic Myeloma Multiplex Hematology 2024 Standard Therapy Poland 57
    1870 Apheresis Allogeneic Diffuse large B-cell lymphoma Hematology 2024 Standard Therapy Poland 17
    1871 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 48
    1872 Apheresis Allogeneic Chronic lymphocytic leukemia Hematology 2024 Standard Therapy Germany 63
    1873 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 65
    1874 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 64
    1875 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 76
    1876 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 44
    1877 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 62
    1878 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy NETHERLANDS 25
    1879 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy USA 42
    1880 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy CROATIA 66
    1881 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 70
    1882 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Switzerland 68
    1883 Apheresis Allogeneic Chronic Myelomonocytic Leukaemia Hematology 2024 Standard Therapy NETHERLANDS 62
    1884 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy USA 58
    1885 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 62
    1886 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Belarus 54
    1887 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Spain 9
    1888 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 66
    1889 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy France 67
    1890 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy France 54
    1891 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy South Africa 54
    1892 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 60
    1893 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Sweden 60
    1894 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Spain 67
    1895 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 66
    1896 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 53
    1897 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
    1898 Apheresis Autologous Non-Hodgkin Lymphoma, rezidiv Hematology 2024 Standard Therapy Germany 64
    1899 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 57
    1900 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 66